Blog Posts

Oncogene Cancer Research

Apr 5, 2025, 11:53

Biomarker testing means being put on the right treatment at the right time – Oncogene Cancer Research

Oncogene Cancer Research shared a post on LinkedIn:

“Our co-founder Jan Clark’s daughter Amy was diagnosed with stage 4 lung cancer at just 20 years old. Amy was told she would need to go in chemo but a biomarker test revealed an ALK-positive mutation.

This meant Amy went on to take a targeted therapy – an oral medication that inhibits her cancer and is much more tolerable. Five years on, Amy is still on that treatment, works full-time and has a full life.

Here Jan explains more.

Biomarker testing means being put on the right treatment at the right time. Please help us create more awareness of biomarker testing by sharing.

Thank you to Lung Cancer Europe for the creation of this film.”

ALK-positive mutation biomarker testing cancer fight against cancer Global fight against cancer Jan Clark Lung cancer Lung Cancer Europe OncoDaily Oncogene Cancer Research Oncology

Top 10 Oncogrants of the Week: Advancing Breakthroughs in Cancer Care

Solange Peters Honored with the IASLC Paul A. Bunn, Jr. Scientific Award 2025

World Radiotherapy Awareness Day, September 7: Recognizing the Hidden Hero of Cancer Care

16 Posts Not to Miss From WCLC 2025 Part 1

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham